Strong organic revenue growth
Group revenue grew +6.1% like-for-like in FY2025 (nearly +15% over 2 years). Nursing homes led the expansion with revenue up +8.1% YoY; clinics were more muted (+2.5%). Growth drivers were a +3.3ppt price effect, +1.8ppt occupancy effect and +1.0% from ramp-up of new facilities.
Occupancy recovery
Average occupancy rose by ~1.8 percentage points to 87.6% (end-2025 vs end-2024). Nursing homes occupancy increased ~2.0ppt to 87.2% and is ~5ppt higher versus 2023; overall improvement since 2021 is ~7.6ppt.
Substantial margin and EBITDA improvements
Like-for-like EBITDA growth beat guidance at +19% for FY2025. EBITDA before IFRS16 rose by €135m (+58.3% like-for-like). EBITDAR also reported strong growth (management cited +58%), with H2 showing continued momentum.
Cash flow turnaround and large free cash flow
Net operating cash flow improved from €15m in FY2024 to €190m in FY2025. Free cash flow turned positive at €347m versus -€298m a year earlier (improvement >€600m). Recurring free cash flow was positive in H2 at €20m.
Successful disposal program and liquidity added
Disposals since mid-2022 reached €2.35bn (exceeding the prior €1.5bn target). Disposals closed in 2025 totaled ~€602m, with ~€216m signed but not yet cashed. The Isemia transaction (closed 14 Jan) added ~€703m liquidity.
Major deleveraging and refinancing completed
Entire bank debt refinanced with €3.15bn of new financing (Euribor 3M +247bps cash / +363bps incl. PIK). Pro forma net debt fell by ~€1.0bn year-over-year to ~€3.8bn; reported net debt (ex IFRS5/16) €4.5bn. Leverage improved to 9.9x pro forma (from ~19.5x prior year).
Quality, ESG and operational KPIs improved
Real estate portfolio valued at €5.6bn; 44% of beds owned. French resident satisfaction reached 93.4% (+50bps vs 2024; >+3.0pts vs 2022). Net Promoter Score rose to 41 (+4 vs 2024; +23 vs 2022). Employee engagement launched at 62%; employee turnover declined. Energy consumption down ~9% YoY.
Confident near-term guidance
Company reaffirmed medium-term guidance and expects EBITDA to grow at least +10% in 2026 at constant perimeter and an average CAGR >15% for 2024–2026. Management expects continued operational leverage to support margins.